Results 41 to 50 of about 1,625,326 (183)

A case of acute disseminated encephalomyelitis following Mycoplasma pneumoniae infection

open access: yesIDCases, 2018
We report a case of acute disseminated encephalomyelitis (ADEM) secondary to Mycoplasma pneumoniae infection that failed to improve with methylprednisolone and intravenous immunoglobulin (IVIG); who responded with plasmapheresis.
Alla Laila   +3 more
doaj   +1 more source

A case of acute disseminated encephalomyelitis following dengue infection

open access: yesCHRISMED Journal of Health and Research, 2015
Neurological manifestations after dengue are not very common and acute disseminated encephalomyelitis (ADEM) following dengue infections is still more infrequent. Few cases have been documented in literature.
Subrata Chakrabarti
doaj   +1 more source

Acute disseminated encephalomyelitis with optic neuritis and mononeuritis multiplex following COVID-19 vaccination: case report

open access: yesThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023
Background Acute disseminated encephalomyelitis (ADEM) is an extremely rare complication of COVID-19 vaccination with very few reports worldwide. Concomitant peripheral nervous tissue involvement in ADEM is very uncommon.
Jomal Mathew Chittilappilly   +1 more
doaj   +1 more source

A case of acute disseminated encephalomyelitis (ADEM) [PDF]

open access: yesJournal of Analytical Research in Clinical Medicine, 2019
Introduction: Acute disseminated encephalomyelitis (ADEM) is an uncommon monophasic idiopathic inflammatory demyelinating disease. ADEM typically presents with non-specific symptoms including nausea, vomiting, fever, and headache. This then progresses to neurological deficits such as motor weakness, altered sensorium, and often significant morbidity or
Saba Nemati-Ahmadabad   +3 more
openaire   +1 more source

Acute Disseminated Encephalomyelitis [PDF]

open access: yes, 2009
Acute disseminated encephalomyelitis (ADEM) is an acute, inflammatory, monophasic, demyelinating and immune-mediated disorder of central nervous system; occurs mostly in children after systemic viral infections or vaccinations.
Sotoudeh, Kambiz, Khosroshahi, Nahid
core   +2 more sources

ADEM-_Supp-Table-Sept23 - Increased Intracranial Pressure in Acute Disseminated Encephalomyelitis

open access: yes, 2019
ADEM-_Supp-Table-Sept23 for Increased Intracranial Pressure in Acute Disseminated Encephalomyelitis by Rotem Orbach, Nira Schneebaum Sender, Ronit Lubetzky, and Aviva Fattal-Valevski in Journal of Child ...
Nira Schneebaum Sender (6018467)   +3 more
core   +1 more source

Dengue Fever as A Cause of Acute Disseminated Encephalomyelitis (ADEM)

open access: yes, 1970
Dengue fever is very common in Bangladesh. Every year a large number of urban populations suffer from this viral infection. Various presentations of dengue fever have been documented.
T Miah   +6 more
core   +1 more source

Acute Disseminated Encephalomyelitis Following Completion of Pneumococcal Meningitis Treatment: A Case Report and Review of the Literature

open access: yesMediterranean Journal of Infection, Microbes and Antimicrobials, 2023
Acute disseminated encephalomyelitis (ADEM) is an immune-mediated inflammatory disease of the central nervous system (CNS) and is commonly seen in children.
Ayşe Serra ÖZEL   +5 more
doaj   +1 more source

Acute Disseminated Encephalomyelitis (ADEM)

open access: yes, 2018
A 6-year-old girl suffered from frequent blinking for 1 month. She visited a local ophthalmologist and was found to have optic atrophy in both eyes. She also complained of frequent headaches. Her best-corrected visual acuity was 5/60 in both eyes. Anterior segments were normal. Fundoscopic examination showed optic atrophy in both eyes (Fig. 20.1).
  +4 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy